It is my pleasure to welcome all of you to Imagion Biosystems’ Annual General Meeting of Shareholders for the financial year ending 31 December 2021.
I am especially delighted, finally, to return to Australia to join my fellow Directors and colleagues to host this meeting as a hybrid forum and to make ourselves available to meet face-to-face.
Before attending to the formal business of the meeting, I would like to take this opportunity to reflect on our accomplishments of 2021 and provide some insight regarding what we anticipate for the near future.
Our MagSense® technology is designed to provide non-invasive detection of cancer and other diseases without the risks associated with radiation-based imaging technologies.
Additionally, by using cancer-specific targeting molecules we aim to eliminate unnecessary biopsies that are performed when standard imaging identifies a suspicious lesion but can’t confirm if it is a malignant or benign growth.
The prospective value and benefit to patient care of our approach was recognized by the FDA with the Breakthrough Device designation in 2019 and bringing this first-of-its-kind innovation from concept to clinic has been our sole mission…
Questions about this transcript or other investor-related inquiries? Please email our investor relations department at: firstname.lastname@example.org.